| Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents RCA van Linschoten, E Visser, CD Niehot, CJ van Der Woude, ... Alimentary pharmacology & therapeutics 54 (3), 234-248, 2021 | 79 | 2021 |
| Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised … RCA van Linschoten, FM Jansen, RWM Pauwels, LJT Smits, F Atsma, ... The Lancet Gastroenterology & Hepatology 8 (4), 343-355, 2023 | 14 | 2023 |
| Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period RCA van Linschoten, N van Leeuwen, D Nieboer, E Birnie, ... BMJ open 12 (1), e050539, 2022 | 7 | 2022 |
| Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options AR Bourgonje, RCA van Linschoten, RL West, MA van Dijk, ... Therapeutic advances in gastroenterology 14, 17562848211012595, 2021 | 7 | 2021 |
| Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study LJT Smits, RWM Pauwels, W Kievit, DJ De Jong, AC de Vries, F Hoentjen, ... BMJ open 10 (5), e035326, 2020 | 6 | 2020 |
| Dutch normative data of the sexual distress scale and the body image scale AS Huberts, NJMCV Peeters, ZLR Kaplan, RCA van Linschoten, ... Quality of Life Research 32 (10), 2829-2837, 2023 | 4 | 2023 |
| Cost-effectiveness analysis of increased adalimumab dose intervals in Crohn’s disease patients in stable remission: the randomized controlled LADI trial FM Jansen, RCA van Linschoten, W Kievit, LJT Smits, RWM Pauwels, ... Journal of Crohn's and Colitis 17 (11), 1771-1780, 2023 | 3 | 2023 |
| Handling missing values in the analysis of between-hospital differences in ordinal and dichotomous outcomes: a simulation study RCA Van Linschoten, M Amini, N Van Leeuwen, F Eijkenaar, ... BMJ Quality & Safety 32 (12), 742-749, 2023 | 2 | 2023 |
| OP25 prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative data R Van Linschoten, N van Leeuwen, JA Hazelzet, CJ van der Woude, ... Journal of Crohn's and Colitis 17 (Supplement_1), i34-i35, 2023 | 2 | 2023 |
| Midline Surface Area of the Corpus Callosum in Children with Attention-deficit/Hyperactivity Disorder: A Systematic Review RCA van Linschoten, D Clydesdale, B Dierckx, SE Mous Erasmus Journal of Medicine 3 (2), 38-42, 2013 | 2 | 2013 |
| Prevalence, incidence and mortality of inflammatory bowel disease in the Netherlands: development and external validation of machine learning models RCA van Linschoten, N van Leeuwen, D van Klaveren, PMJ Pierik, ... Journal of Crohn's and Colitis, jjaf017, 2025 | 1 | 2025 |
| CastorEDC API: a python package for managing real world data in castor electronic data capture RCA van Linschoten, SL Knijnenburg, RL West, D van Noord Journal of Open Research Software 11 (1), 2023 | 1 | 2023 |
| Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease RCA van Linschoten, AS Huberts, N van Leeuwen, JA Hazelzet, ... Therapeutic Advances in Gastroenterology 16, 17562848231202159, 2023 | 1 | 2023 |
| Digital outcome measurement to improve care for patients with immune-mediated inflammatory diseases: protocol for the IMID registry AEM Looijen, RCA van Linschoten, JD Brugma, DJ Hijnen, PHP de Jong, ... JMIR Research Protocols 12 (1), e43230, 2023 | 1 | 2023 |
| Variation Between Hospitals in Outcomes and Costs of IBD Care: Results From the IBD Value Study RCA van Linschoten, CJ van der Woude, E Visser, N van Leeuwen, ... Inflammatory Bowel Diseases 31 (2), 332-343, 2025 | | 2025 |
| P1251 A Care Pathway for Inflammatory Bowel Disease can Reduce Healthcare Costs and is Cost-Effective E Visser, AM Oude Voshaar, R van Linschoten, A Bodelier, C Fitzpatrick, ... Journal of Crohn's and Colitis 19 (Supplement_1), i2264-i2265, 2025 | | 2025 |
| P0860 Long-term outcomes of extended versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission: 3-year follow-up of the randomized … M Devillers, L van Lierop, R van Linschoten, F Jansen, N den Broeder, ... Journal of Crohn's and Colitis 19 (Supplement_1), i1638-i1639, 2025 | | 2025 |
| P0624 Adherence to a Care Pathway for Inflammatory Bowel Disease in the Southwest region of the Netherlands E Visser, S Allers, R van Linschoten, A Bodelier, C Fitzpatrick, V de Jong, ... Journal of Crohn's and Colitis 19 (Supplement_1), i1233-i1233, 2025 | | 2025 |
| P0952 Effect of a Care Pathway for Inflammatory Bowel Disease on Patient Outcomes and Healthcare Utilization: results of the IBD Value Study E Visser, R van Linschoten, A Bodelier, C Fitzpatrick, V de Jonge, ... Journal of Crohn's and Colitis 19 (Supplement_1), i1781-i1781, 2025 | | 2025 |
| Predicting mucosal inflammation in IBD patients using patient-reported symptom scores and a faecal calprotectin home test: protocol for a multicentre prospective validation study L Janssen, RCA van Linschoten, RL West, LPL Gilissen, ... BMJ open 14 (10), e076290, 2024 | | 2024 |
Rachel WestGastroenterologist Franciscus Gasthuis&VlietlandZweryfikowany adres z franciscus.nl
